Dropprint Genomics

Dropprint Genomics was a private biotechnology company focused on single-cell genomics and machine learning tools to characterize the immune system for drug discovery and immune health applications. The company developed cell technology and computational models that profiled genes in individual cells and generated personalized immune-system maps. Its offerings were positioned as an enabling platform for target discovery and translational research rather than as a developer of named therapeutic drug candidates. Founded in 2019 in the San Francisco Bay Area, the company participated in Y Combinator and raised seed financing before being acquired by Immunai in March 2021. Following the acquisition, Dropprint Genomics became part of Immunai and its standalone operations and branding were folded into the parent organization.